About Nu Skin Enterprises, Inc. Common Stock (NUS)
Nu Skin Enterprises is a global company that specializes in personal care products and dietary supplements. They focus on innovating and marketing anti-aging skincare items, hair care products, and nutritional supplements through a direct selling model. The company emphasizes the use of science and technology in developing its products, which are designed to enhance the overall well-being and appearance of its customers. By combining traditional retail with a network of independent distributors, Nu Skin provides a unique shopping experience that leverages personal connections and social selling strategies. Read More
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on.
But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Olaplex (NASDAQ:OLPX) and the rest of the personal care stocks fared in Q4.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the personal care industry, including Nu Skin (NYSE:NUS) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Inter Parfums (NASDAQ:IPAR) and the best and worst performers in the personal care industry.
Nu Skin Enterprises, Inc. (NYSE: NUS) today announced it will release first quarter 2025 results after the market closes on Thursday, May 8. The Nu Skin management team will host a conference call with the investment community later that same day at 5 p.m. ET. During the call, management will discuss recent results and upcoming business initiatives.
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Personal care company Nu Skin (NYSE:NUS) reported Q4 CY2024 results topping the market’s revenue expectations, but sales fell by 8.8% year on year to $445.6 million. On the other hand, next quarter’s revenue guidance of $355 million was less impressive, coming in 12.3% below analysts’ estimates. Its non-GAAP profit of $0.38 per share was 72.3% above analysts’ consensus estimates.
Nu Skin Enterprises, Inc. (NYSE: NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on March 5, 2025, to shareholders of record on Feb. 24, 2025.
Shares of personal care company Nu Skin (NYSE:NUS)
jumped 13.3% in the morning session after the company reported strong preliminary Q4 2024 guidance, with revenue expected to be at the high end of the previous guidance range. A day after this report, the company is expected to share updates on its strategy, including the recent sale of Mavely for $250 million. Overall, the updates provide more reasons for investors to stay optimistic.
Nu Skin Enterprises Inc. (NYSE: NUS) today announced Q4 2024 preliminary revenue at the high end of the company’s guidance range ahead of its presentation at the ICR Conference on Tuesday, Jan. 14. President and CEO Ryan Napierski and CFO James Thomas will participate in a moderated fireside chat to discuss company strategy and the state of the business, including the recent strategic transaction of Mavely for $250 million.
